Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Withdrawn before enrolling

Conditions studied: Renal Cell Carcinoma

In brief

A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents

Key facts

Study ID

NCT02928263

Run by

Bristol-Myers Squibb

People needed

0

Starts

2017-02-28

Expected to finish

2017-05-31

Last updated by the study team

2017-07-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis with metastatic renal cell carcinoma
• Prescription/administration of one of the IV or oral agents examined in the study

You may not qualify if…

• Patients with other primary cancer diagnosis before RCC diagnosis
• Patients with pregnancy or HIV/AIDS

Where it is running

• Bristol-Myers Squibb — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.